ERBB2 and colorectal carcinoma: Consistently, our data showed that HER2 was positive in 74% (398/538) of 538 human CRC patient specimens using immunohistochemistry assay, and HER2 revealed strong, moderate, low, and negative staining intensities in 6% (34/538, 40% (216/538), 28% (148/538) and 26% (140/538) of specimens, respectively (Fig. 1B–C).